Schneegurt Noah R, Wright Christian, Glenn Neil, Thethi Inderpal
Internal Medicine, Mount Carmel Health System, Grove City, USA.
Pulmonary and Critical Care Medicine, Mount Carmel Health System, Columbus, USA.
Cureus. 2024 Jun 4;16(6):e61637. doi: 10.7759/cureus.61637. eCollection 2024 Jun.
Flecainide is an antiarrhythmic drug that rarely causes lung injury. We present a case of flecainide-induced lung injury (FILI) that resulted in acute respiratory distress syndrome (ARDS) and resolved after flecainide discontinuation and corticosteroid treatment. FILI has been shown to occur days to two years after treatment initiation. Our presented case shows that FILI can occur after at least five years of therapy and is the first to show lung injury after a period of flecainide cessation and subsequent re-initiation. Clinical impacts may be large, as flecainide becomes more commonplace in medical pharmacopeia.
氟卡尼是一种很少引起肺损伤的抗心律失常药物。我们报告一例氟卡尼诱发的肺损伤(FILI),该损伤导致急性呼吸窘迫综合征(ARDS),在停用氟卡尼并进行皮质类固醇治疗后病情得到缓解。已证明FILI在治疗开始后数天至两年内发生。我们报告的病例表明,FILI可在至少五年的治疗后发生,并且是首例在氟卡尼停药一段时间后重新开始使用又出现肺损伤的病例。随着氟卡尼在医学药典中变得越来越常见,其临床影响可能很大。